Literature DB >> 23117005

Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?

Hashim Uddin Ahmed1, Manit Arya, Alex Freeman, Mark Emberton.   

Abstract

Prostate cancer is generally multifocal and consists of a dominant focus-measured by tumour volume and deemed the index lesion-and one or more separate, secondary tumour foci of smaller volume. Much laboratory and clinical evidence has shown that we need to rethink how we regard low-grade and low-volume prostate lesions. In this Personal View, we discuss why small, low-grade Gleason pattern prostate lesions, which are currently designated as prostate cancer, could be regarded as non-malignant. These lesions either do not meet the criteria of the hallmarks of cancer or robust evidence that they do so is absent, by contrast with large lesions with a high Gleason grade, which seem to cause most metastatic disease.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23117005     DOI: 10.1016/S1470-2045(12)70388-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  52 in total

Review 1.  Image-guided robotic interventions for prostate cancer.

Authors:  Ashwin N Sridhar; Archie Hughes-Hallett; Erik K Mayer; Philip J Pratt; Philip J Edwards; Guang-Zhong Yang; Ara W Darzi; Justin A Vale
Journal:  Nat Rev Urol       Date:  2013-06-18       Impact factor: 14.432

2.  Quantitative identification of magnetic resonance imaging features of prostate cancer response following laser ablation and radical prostatectomy.

Authors:  Geert J S Litjens; Henkjan J Huisman; Robin M Elliott; Natalie Nc Shih; Michael D Feldman; Satish Viswanath; Jurgen J Fütterer; Joyce G R Bomers; Anant Madabhushi
Journal:  J Med Imaging (Bellingham)       Date:  2014-10-27

Review 3.  Gleason 6 Prostate Cancer: Translating Biology into Population Health.

Authors:  Scott E Eggener; Ketan Badani; Daniel A Barocas; Glen W Barrisford; Jed-Sian Cheng; Arnold I Chin; Anthony Corcoran; Jonathan I Epstein; Arvin K George; Gopal N Gupta; Matthew H Hayn; Eric C Kauffman; Brian Lane; Michael A Liss; Moben Mirza; Todd M Morgan; Kelvin Moses; Kenneth G Nepple; Mark A Preston; Soroush Rais-Bahrami; Matthew J Resnick; M Minhaj Siddiqui; Jonathan Silberstein; Eric A Singer; Geoffrey A Sonn; Preston Sprenkle; Kelly L Stratton; Jennifer Taylor; Jeffrey Tomaszewski; Matt Tollefson; Andrew Vickers; Wesley M White; William T Lowrance
Journal:  J Urol       Date:  2015-04-04       Impact factor: 7.450

4.  Prostate imaging--the future is now: current concepts and future potentials.

Authors:  Felix K-H Chun; Thomas R W Herrmann
Journal:  World J Urol       Date:  2014-08       Impact factor: 4.226

5.  A dynamic lesion model for differentiation of malignant and benign pathologies.

Authors:  Weiguo Cao; Zhengrong Liang; Yongfeng Gao; Marc J Pomeroy; Fangfang Han; Almas Abbasi; Perry J Pickhardt
Journal:  Sci Rep       Date:  2021-02-10       Impact factor: 4.379

6.  Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.

Authors:  Henk van der Poel; Laurence Klotz; Gerald Andriole; Abdel-Rahmène Azzouzi; Anders Bjartell; Olivier Cussenot; Freddy Hamdy; Markus Graefen; Paolo Palma; Arturo Rodriguez Rivera; Christian G Stief
Journal:  World J Urol       Date:  2015-06-03       Impact factor: 4.226

7.  Natural history of prostatic lesions on serial multiparametric magnetic resonance imaging.

Authors:  Samrad Ghavimi; Hamidreza Abdi; Jennifer Waterhouse; Richard Savdie; Silvia Chang; Alison Harris; Lindsay Machan; Martin Gleave; Alan I So; Larry Goldenberg; Peter C Black
Journal:  Can Urol Assoc J       Date:  2018-04-06       Impact factor: 1.862

8.  Comparison of free-hand transperineal mpMRI/TRUS fusion-guided biopsy with transperineal 12-core systematic biopsy for the diagnosis of prostate cancer: a single-center prospective study in China.

Authors:  Qing Zhang; Wei Wang; Bing Zhang; Jong Shi; Yao Fu; Danyan Li; Suhan Guo; Shengjie Zhang; Haifeng Huang; Xuping Jiang; Weimin Zhou; Hongqian Guo
Journal:  Int Urol Nephrol       Date:  2016-12-22       Impact factor: 2.370

9.  Validation of the current eligibility criteria for focal therapy in men with localized prostate cancer and the role of MRI.

Authors:  Raisa S Pompe; Bieke Kühn-Thomä; Yamini Nagaraj; Valia Veleva; Felix Preisser; Sami-Ramzi Leyh-Bannurah; Markus Graefen; Hartwig Huland; Derya Tilki; Georg Salomon
Journal:  World J Urol       Date:  2018-02-28       Impact factor: 4.226

Review 10.  Active surveillance for low-risk prostate cancer.

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2015-04       Impact factor: 3.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.